Clinical Trial: A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07188896) titled 'A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)' on Sept. 16.

Brief Summary: This three-arm randomized phase 2 trial will enroll advanced clear cell RCC patients (all IMDC risk groups). Patients will be randomized 2:2:1 to either Arm A (fianlimab/ cemiplimab/ ipilimumab), Arm B (fianlimab/ cemiplimab), or Arm C (standard ipilimumab/ nivolumab), respectively.

Study Start Date: Nov., 2025

Study Type: INTERVENTIONAL

Condition: Advanced Renal Cell Carcinoma (aRCC) Metastatic Renal Cell Carcinoma ( mRCC) Clear Cell Renal Cell Carcino...